Skip to main content
    C

    Centessa Pharmaceuticals PLC ADR (CNTA)

    Official site

    BIOTECHNOLOGY

    $40.50
    +0.00 (+0.00%)

    Last updated: Jun 25, 2026 at 5:00 PM ET

    Centessa Pharmaceuticals PLC ADR (CNTA) Financials: Revenue, Profit and Cash Flow

    Updated May 5, 2026. Financial statements from company filings, amounts in US dollars.

    Centessa Pharmaceuticals PLC ADR reported revenue of $15.00M for the fiscal year ended Dec 31, 2025. That year, net income was -$197.53M with a net margin of -1316.9%, operating cash flow was -$193.82M and free cash flow was -$194.19M. The quarter ended Mar 31, 2026 had revenue of $0 and net income of -$79.24M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$15.00MN/A100.0%-1384.6%-1316.9%
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$6.85MN/A100.0%-2499.4%-2204.7%
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Mar 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$15.00M$0$6.85M$0$0$0$0
    Gross profit$15.00M$0$6.85M$0$0$0$0
    Research and development$172.22M$150.24M$124.41M$155.08M$96.32M$9.30M$4.26M
    Operating income-$207.69M-$201.06M-$171.28M-$212.26M-$374.87M-$10.44M-$5.05M
    Net income-$197.53M-$235.76M-$151.09M-$216.21M-$381.90M-$10.66M-$5.28M
    EBITDA-$183.33MN/A-$165.43M-$209.55M-$139.30M-$10.29M-$5.05M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Revenue$0$0$0$0$15.00M$0$0$0$0$6.85M$0$0
    Gross profit-$238.60K$0$0$0$15.00M$0$0$0$0$6.85M$0$0
    Operating income-$79.77M-$68.47M-$53.79M-$54.65M-$30.78M-$74.58M-$46.41M-$43.98M-$36.09M-$35.18M-$40.21M-$47.02M
    Net income-$79.24M-$66.16M-$54.89M-$50.34M-$26.14M-$111.33M-$42.57M-$43.82M-$38.05M-$36.84M-$38.65M-$24.89M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $7.57M by $53.73M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$687.50M$576.80M$360.25M$444.31M$629.63M$11.72M$19.73M
    Current assets$367.88M$536.41M$315.09M$437.75M$628.77M$11.16M$19.23M
    Cash and equivalents$61.30M$383.22M$128.03M$393.64M$595.08M$7.23MN/A
    Total liabilities$160.63M$175.25M$124.00M$108.14M$138.08M$8.62M$6.07M
    Short-term debt$0$0$0$0$0$5.63M$544.00K
    Long-term debt$7.57M$108.94M$75.70M$69.80M$75.70M$0$3.62M
    Shareholder equity$526.86M$401.55M$236.24M$336.17M$491.55M$3.10M$13.66M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total assets$641.76M$687.50M$448.30M$492.13M$527.85M$576.80M$609.72M$398.85M$328.17M$360.25M$377.36M$392.92M
    Total liabilities$154.41M$160.63M$146.73M$147.21M$141.60M$175.25M$110.58M$111.88M$113.01M$124.00M$117.97M$116.31M
    Cash and equivalents$62.43M$61.30M$50.81M$44.24M$105.16M$383.22M$395.03M$127.37M$118.22M$128.03M$171.50M$145.22M
    Shareholder equity$487.35M$526.86M$301.57M$344.92M$386.25M$401.55M$499.14M$286.96M$215.16M$236.24M$259.39M$276.61M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$193.82M-$142.06M-$160.34M-$200.55M-$136.14M-$10.63M-$5.83M
    Capital expenditures$371.00K$34.00K$169.00K$1.14M$185.98K$0$0
    Free cash flow-$194.19M-$142.09M-$160.51M-$201.68M-$136.33M-$10.63M-$5.83M
    Share repurchases$0$0$0$0$12.00K$0$0
    Investing cash flow-$418.53M$31.27M-$127.00M-$931.00K$63.25M$0$0
    Financing cash flow$291.53M$364.75M$21.12M$457.00K$660.07M$1.36M$9.01M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Operating cash flow-$72.22M-$55.81M-$58.31M-$22.45M-$57.25M-$42.80M-$21.39M-$40.58M-$37.29M-$31.10M-$37.39M-$44.06M
    Capital expenditures$0$11.00K$234.00K$126.00K$3$0$34.00K$1$0$28.03K$43.00K$10.00K
    Free cash flow-$72.22M-$55.82M-$58.55M-$22.58M-$57.25M-$42.80M-$21.42M-$40.58M-$37.29M-$31.13M-$37.44M-$44.07M
    Last 12 quarters

    Frequently Asked Questions About CNTA

    What is Centessa Pharmaceuticals PLC ADR's annual revenue?

    Centessa Pharmaceuticals PLC ADR reported revenue of $15.00M for the fiscal year ended Dec 31, 2025.

    Is Centessa Pharmaceuticals PLC ADR profitable?

    No. Centessa Pharmaceuticals PLC ADR reported net income of -$197.53M for the fiscal year ended Dec 31, 2025, with a net margin of -1316.9%.

    How much free cash flow does CNTA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$193.82M minus capital expenditures of $371.00K produced free cash flow of -$194.19M.

    How much debt does Centessa Pharmaceuticals PLC ADR have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $7.57M, short-term debt of $0 and cash and equivalents of $61.30M.

    What is CNTA's profit margin?

    For the fiscal year ended Dec 31, 2025, Centessa Pharmaceuticals PLC ADR reported gross margin of 100.0%, operating margin of -1384.6% and net margin of -1316.9%.